<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

Storm Therapeutics


STORM Therapeutics is a University of Cambridge spin-out, translating the groundbreaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases (“Harnessing the power of RNA epigenetics”) and is the only company attempting to treat disease by drugging the enzymes that modify RNA. STORM Therapeutics is building the world’s leading discovery effort in RNA epigenetics through academic collaborations and commercial partnerships.

The company is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures and Touchstone Innovations who invested a £12m series A in June 2016 and who share the founders’ ambitions to build a world-leading company in the field. STORM Therapeutics occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK.